Pharmacokinetic study of aniracetam in elderly patients with cerebrovascular disease.
The clinical pharmacokinetics of the cognitive enhancer, aniracetam (200 mg), was studied in elderly patients with cerebrovascular disease (CVD) and compared with those of young healthy volunteers. Six female hospitalized patients (mean age 84.5 years) were used in this study. The serum level of anisic acid and p-methoxyhippuric acid, major metabolites of aniracetam, reached a peak at 2 h after oral administration, and returned to basal level by 6 h. Mean creatinine clearance was 20-30 ml/min. The t1/2 of metabolites was increased by 4- to 7-fold in the elderly patients compared with young volunteers. This study showed that tmax, t1/2, and AUC were enlarged in the elderly; however, no clinical side effects were observed.
Endo
H
H
Department of Geriatrics, National Chubu Hospital, Ohbu, Japan.
Tajima
T
T
Yamada
H
H
Igata
A
A
Yamamoto
Y
Y
Tsuchida
H
H
Nakashima
Y
Y
Suzuki
Y
Y
Ikari
H
H
Iguchi
A
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019540:Area Under Curve; D001711:Biotransformation; D002561:Cerebrovascular Disorders / Q000378:metabolism*; D005260:Female; D006207:Half-Life; D006801:Humans; D018697:Nootropic Agents / Q000009:adverse effects / Q000493:pharmacokinetics*; D011760:Pyrrolidinones / Q000009:adverse effects / Q000493:pharmacokinetics*
D018697:Nootropic Agents; D011760:Pyrrolidinones; C036466:aniracetam